Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage

Programmed cell death protein 1 (PD‐1), an immune checkpoint receptor expressed by activated T, B, and NK cells, is a well‐known target for cancer immunotherapy. Tislelizumab (BGB‐A317) is an anti‐PD‐1 antibody that has recently been approved for treatment of Hodgkin's lymphoma and urothelial c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Yuan, Feng, Yingcai, Sun, Hanzi, Zhang, Bo, Wu, Hongfu, Zhu, Qing, Li, Yucheng, Zhang, Tong, Zhang, Yilu, Cui, Xinxin, Li, Zhuo, Song, Xiaomin, Li, Kang, Liu, Mike, Liu, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931243/
https://www.ncbi.nlm.nih.gov/pubmed/33527708
http://dx.doi.org/10.1002/2211-5463.13102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931243/
https://www.ncbi.nlm.nih.gov/pubmed/33527708
http://dx.doi.org/10.1002/2211-5463.13102

Ejemplares similares